News
Oral Corticosteroids Deemed Ineffective for Rhinosinusitis
Systemic corticosteroids are not effective for symptom control in patients with acute rhinosinusitis.
Your search for oral corticosteroids returned 122 results
ATS 2021, News
Oral Corticosteroid Dose Management With Impaired Adrenal Function Evaluated
Patients with normal adrenal function are largely able to eliminate the use of oral corticosteroids or achieve a daily dose of 5 mg or less.
News
Oral Corticosteroid Use May Up Risk of Adverse Effects in Asthma Patients
Compared to the control group, patients who took four or more oral corticosteroid prescriptions had 1.29 times the odds of experiencing a new adverse effect within the year.
Drugs in the Pipeline
Oral Tyrosine Kinase Inhibitor Effective in Severe Asthma Trial
Treatment with masitinib, a selective tyrosine kinase inhibitor, significantly reduces the rate of severe asthma exacerbations in patients with severe asthma uncontrolled by oral corticosteroids, according to data from a phase 3 study.
ATS 2018
Efficacy, Safety of Dupilumab in Corticosteroid-Dependent Severe Asthma
Subcutaneous dupilumab significantly reduced the use of oral corticosteroids in patients with corticosteroid-dependent severe asthma.
Drug News
High Risk of Pulmonary Embolism Seen in Severe Asthma
Patients with asthma are at higher risk of pulmonary embolism, particularly if the asthma is severe or they take oral corticosteroids.
News
Drug-Induced Immunosuppression Examined in US Adults
Drug-induced immunosuppression, particularly from oral corticosteroids, may limit response to COVID-19 vaccine
Drugs in the Pipeline
Benralizumab Reduces OCS Use in Severe Asthma Trial
Findings from a phase 3b trial showed that a majority of patients with severe eosinophilic asthma treated with benralizumab (Fasenra; AstraZeneca), an interleukin-5 antagonist, were able to eliminate or reduce oral corticosteroid (OCS) use. The open-label, single-arm PONENTE trial assessed the efficacy and safety of reducing OCS use after initiating treatment with benralizumab in nearly…
News
Dupixent Approved as Add-On Maintenance Tx for Moderate-to-Severe Asthma
In the asthma clinical trials, the most common adverse reactions were injection site reactions, oropharyngeal pain, and eosinophilia.
ATS 2018
Lung Function in Severe Asthma Improved With Benralizumab
Peak expiratory flow increases were greater with benralizumab than placebo in patients with severe eosinophilic asthma.
